"I guess you better hope that the SUCCEED trial has the majority of its patients NOT in the bone sarcoma category then."
A couple of points you may want to consider. First, the majority of bone sarcomas affect children who, unfortunately, are not eligible for the SUCCEED trial. Second, the most common soft tissue sarcomas are leiomyosarcoma and liposarcoma. To date rida has shown to be particularly efficacious in precisely the sarcomas that are most prevalent.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.